Inhalon Biopharma is developing an inhaled immunotherapy platform for treating acute respiratory infections (ARI), such as syncytial virus (RSV), influenza, metapneumovirus (MPV), parainfluenza virus (PIV), adenovirus, severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS).  Today there are no approved treatments for a wide range of ARIs that can lead to hospitalization, long-term health complications, and sometimes death.

Biotechnology

Inhalon

John Whelan

Bill Picht

Brian Farrer

Jeff Hutchins

Thomas Moench

Sam Lai

The leadership team at Inhalon has experience in the pharmaceutical and biotech industries, as well as academia. Members of the team have served as presidents, CEOs, and directors of companies such as Neuraltus Pharmaceuticals, Heron Therapeutics, and Raven biotechnologies. They have also been professors at universities such as UNC Chapel Hill and Johns Hopkins University.

Leadership Team

CEO and Executive Team

Board of Directors

Leadership Team

About

Team members

Other teams at Inhalon

CEO and Executive Team

Board of Directors